He was quite skeptical about the study, in particular as it doesn't have randomized groups, and e.g. the age difference between control and treatment group was very large. He also didn't consider the virus concentration in the throat to be a good endpoint to measure as from their experiments they know that it goes down over time anyway, and the virus tends to move to the lungs.
Being an antibiotic is also convenient because many times you would also get antibiotics to prevent a secondary infection from bacteria.
It’s not exactly a miracle cure (like an antibiotic is against a bacterial pneumonia), but doctors have few tools when it comes to viral pneumonia, so even something that helps a little is welcome.
I really don't understand why anyone approves such studies. They could've done something useful and we'd know a little bit now.
Next time I am in a burning plane, I'll make sure to refuse a parachute, as the lack of studies means anecdotal evidence tells us basically nothing.
I don't know if Chloroquine works, but I'm pretty sure Chloroquine is no parachute (i.e. it's not a drug where the benefits are so obvious that it doesn't need a proper trial).
That is very true. But unless we are to argue that the virus is not what causes the disease, using the viral load as a proxy for clinical status and contagiousness is acceptable. And unless the effect is small enough that sample selection can affect the conclusion, it doesn't matter much in practice.
I meean, for chloroquine, we have studies showing non inferiority and strong effects. We will not know if it works according to modern standards of statistics using direct survival statistics for another two weeks at best. What to do in the meantime?
In this article, the comparison to flossing in the intro is not good: lack of flossing does not entail mortality rate >.5%.
And all the other approaches selected for study do not feature infectious agents creating a risk of death, so the conclusions of the article are not very transposable to the problem here. For chemotherapy, surgery, etc. yes, they have a point. For microbiology, no.
Everybody seems to be doing armchair critique of the methodology used. I respect the desire to understand, but I believe the critique stands: we do not have RCT for parachutes. And at the moment, we do not have RCT for chloroquine either. We have a long experience of using it for other diseases. It's an old drug with well known side effects and toxicity.
If you are infected, you are free to wait until there is a trial to accept the drug. Yet, based on the information available, I still think it is a wrong decision, akin to asking for a RCT on parachutes aboard a burning plane.
I read through the paper, and it's not immediately obvious, but if you look at the two graphs at the bottom, the hydroxychloroquine is 75% effective in the first chart, but only 50% in the second one. That's because the actual test was:
Control: 16
hydroxychloroquine: 14
hydroxychloroquine + azithromycin: 6
The first chart includes all 20 people who got hydroxychloroquine - including the 6 who also got azithromycin.
My question: do we know how effective azithromycin would be on it's own? Maybe it's the wonder drug we should be focused on, which would be great since it's available everywhere.
It should go without saying these are VERY preliminary results from a small trial but it's something!